News Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
- Oct 22, 2019~ Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~
DEER PARK, Ill., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Oct 21, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced select unaudited preliminary financial results for the third quarter ended September 30, 2019. Select Preliminary...
- Oct 17, 2019NATESTO ® shown to significantly increase mean testosterone levels, while maintaining sufficient gonadotropins to preserve fertility
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced the presentation of data from the NATESTO® Spermatogenesis Study as part of the “Late...
- Oct 15, 2019New Indication Allows Dentists to Remove Crowns and Veneers in Five Minutes or Less with Waterlase Dental Lasers
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, is proud to announce that Waterlase dental lasers received U.S. and Canada regulatory clearance for crown and veneer removal. This...
- Oct 02, 2019— Potential to be First FDA-Approved Drug for ADT induced Hot Flashes – — Topline Clinical Data Anticipated Fall 2019 —
MIAMI, Oct. 02, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer...
- Sep 30, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced that it entered into an amended agreement related to its...
- Sep 27, 2019
FARMINGDALE, N.Y., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices...
- Sep 26, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Sep. 26, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Sep 25, 2019In Vitro Study Establishes Platform for Advancing Implant Technology Through Mechanobiology
4WEB Medical, an orthopedic device company focused on developing innovative implants utilizing its proprietary Truss Implant Technology™ announced today the completion of Phase I in vitro...
- Sep 16, 2019Presentation Scheduled for Today, September 16, 2019, at 4:30 p.m., ET
Dallas, TX, September 16, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced that CEO Winston Black, will...
- Sep 13, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Sep. 13, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Sep 13, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Sep. 13, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Sep 13, 2019DDS Lab will offer Keystone Dental participating dentists exceptional quality, service and value on dental laboratory implants, products and services.
DDS Lab and Keystone Dental have formed a strategic alliance to offer the national dental implant supplier's participating dentists discounted pricing on dental lab implants, products and...
- Sep 06, 2019
Dallas, TX, September 6, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, today announced that its Board of Directors...
- Sep 03, 2019
DEER PARK, Ill., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug...
- Sep 03, 2019SWK Expands Board of Directors to Meet NASDAQ Listing Requirements
Dallas, TX – September 3, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced today that the Company has...
- Aug 28, 2019
MIAMI, Aug. 28, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- Aug 28, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 28, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Aug 28, 2019Company expands implant portfolio with the addition of the Cervical Spine Truss System - Stand-Alone
4WEB Medical, an orthopedic device company focused on developing innovative implants utilizing its proprietary Truss Implant Technology™, announced today that the company has received 510(k)...
- Aug 28, 2019BIOLASE to Participate at Dougherty & Company Institutional Investor Conference on September 5, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced it has been invited to participate at the 4th Annual Dougherty & Company Institutional Investor Conference being...
- Aug 27, 2019
MIAMI, Aug. 27, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- Aug 27, 2019SWK Holdings Corporation acquires 100% of Enteris’ equity
Dallas, TX and Boonton, NJ – August 27, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, and Enteris BioPharma,...
- Aug 21, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 21, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Aug 21, 2019Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence® to Advance Development of Oral KORSUVA™
Boonton, NJ – August 21, 2019 – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary oral peptide delivery technologies, today...
- Aug 19, 2019ET-104 Successfully Demonstrated Bioequivalence to Currently Approved Oral Solid Formulation
DEER PARK, Ill.--(BUSINESS WIRE)--Aug. 19, 2019-- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products...
- Aug 14, 2019
FARMINGDALE, N.Y., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Aug 12, 2019Total revenues of $5.7 million for the second quarter 2019 compared to $6.8 million for the second quarter 2018.
Dallas, TX, August 12, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its second quarter 2019 financial...
- Aug 12, 2019
FARMINGDALE, N.Y., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Aug 08, 2019Promising Clinical Observations for Both Advancing VERU-111 and Zuclomiphene Prostate Cancer Clinical Trials Added VERU-100, Novel First GnRH Antagonist 3 Month Depot Formulation for Androgen Deprivation Had Successful PreNDA meeting with FDA for TADFIN for BPH and NDA Submission Expected in Summer 2020 Company to Host Investor Conference Call on Thursday, August 8, 2019, 8 a.m. ET
MIAMI, Aug. 08, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- Aug 08, 2019--Webcast and conference call today at 4:30 p.m. ET --
BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 8, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Aug 08, 2019Second Quarter Gross Margin Increased Almost 370 Basis Points Year-Over-Year
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today reported net revenue of $8.7 million for the second quarter ended June 30, 2019, a decrease of 29% compared to the second...
- Aug 07, 2019
FARMINGDALE, N.Y., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Aug 07, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three and six-month period...
- Aug 06, 2019ET-203 NDA submitted, Three Additional Product Submissions Expected in 2019
DEER PARK, Ill., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Aug 06, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 6, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Aug 05, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release second quarter 2019 financial and operating results on Thursday, August 8, 2019 after the...
- Aug 02, 2019U.S. market not affected
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that it will voluntarily replace certain NATESTO® lots released in the Canadian and South...
- Aug 01, 2019
MIAMI, Aug. 01, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- Aug 01, 2019-ET-105 assigned Prescription Drug User Fee Act (PDUFA) target action date of March 17, 2020
DEER PARK, Ill., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Aug 01, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 1, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Aug 01, 2019Final study results accepted for “Late Breaking Presentation” on October 16, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that the NATESTO® Spermatogenesis Study results have been accepted for presentation as a...
- Jul 30, 2019
DEER PARK, Ill., July 30, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Jul 30, 2019Acerus Pharmaceuticals to launch U.S. specialty sales force of at least 25 representatives
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that it will be taking an expanded role in the commercialization of NATESTO® in the U.S. The...
- Jul 29, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its second quarter 2019 financial and operating results on Wednesday, August 7, 2019 before the...
- Jul 24, 2019NATESTO® Now Covered on Payer Plans Covering Over 6 Million U.S. Lives
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) announced today that NATESTO® (testosterone nasal gel) is now on formulary...
- Jul 19, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB:ASPCF) today announced that it has entered into a US$5 million subordinated...
- Jul 18, 2019
MIAMI, July 18, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- Jul 18, 2019
FARMINGDALE, N.Y., July 18, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Jul 12, 2019
DEER PARK, Ill., July 12, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Jul 11, 2019Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 immunotherapy can deliver to the peanut allergy community
BRISBANE, Calif.--(BUSINESS WIRE)--Jul. 11, 2019-- Aimmune Therapeutics (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, cautions stakeholders...